|
|
|
| Expression and Clinical Significance of PAX2, AIB1 and MTDH in Breast Cancer Patients |
| TIAN Ya-li, ZHU Jie-bin, GU Min, et al |
| Affiliated hospital of nanjing medical university suzhou municipal hospital oncology jiangsu Xuzhou 215153 |
|
|
|
|
Abstract 【Objective】To investigate the expression and clinical significance of PAX2, AIB1 and MTDH in breast cancer (BC) patients. 【Methods】A total of 200 patients with breast discomfort who underwent pathological examination in our hospital were selected. According to the pathological diagnosis, patients were divided into the breast cancer group and the benign breast lesion group. The expressions of PAX2, AIB1 and MTDH in the two groups were recorded. Furthermore the expression levels of PAX2, AIB1 and MTDH in breast cancer patients with different clinicopathological characteristics were compared. 【Results】The positive expression rate of PAX2 was lower in breast cancer tissue, while the positive expression rates of AIB1 and MTDH were both higher in breast cancer group. The differences were statistically significant (P<0.01). The positive expression rate of PAX2 was lower in breast cancer patients with moderate or low differentiation, lymph node metastasis and infiltration depth staging T3+T4 (P<0.01).The positive expression rates of AIB1 and MTDH in breast cancer patients with moderate or low differentiation, lymph node metastasis and infiltration depth staging T3+T4 were higher (P<0.01). There was no significant difference in the positive expression rates of PAX2, AIB1, and MTDH in breast cancer patients of different ages (P>0.05). Regression analysis results showed that lymph node metastasis and depth of infiltration were the factors affecting the expression of PAX2, AIB1 and MTDH in breast cancer. 【Conclusion】PAX2 positive expression rate is lower in breast cancer patients, while AIB1 and MTDH positive expression rates are higher. Also those expression rates are closely related to lymph node metastasis and depth of infiltration.
|
|
Received: 25 April 2019
|
|
|
|
|
|
[1] Kayar R, ilengirogˇlu V. Correction to “Breast Volume Asymmetry Value, Ratio, and Cancer Risk”[J].Breast Cancer,2017,10(05):267-269.
[2] Benzina S, Beauregard A, Guerrette R,et al.Pax-5 is a potent regulator of E-cadherin and breast cancer malignant processes[J].Oncotarget,2017,8(7):45-47.
[3] Benzina S, Harquail J, Guerrette R,et al.Breast Cancer Malignant Processes are Regulated by Pax-5 Through the Disruption of FAK Signaling Pathways[J].J Cancer,2016,7(14):2035-2044.
[4] 董超,罗春香,陈印,等. 下调MTDH基因表达对乳腺癌MCF-7细胞增殖及凋亡的影响[J].山东医药,2018,58(09):34-36.
[5] Wong-Brown M, Avery-Kiejda K, Scott RJ. Genetic insights into breast cancer risk[J].Hered Cancer Clin Pract,2015,13(1):34-36.
[6] 王志新,于晶晶,刘颖,等.卵生物电阻抗分析在乳腺癌术后上肢淋巴水肿疗效观察中的应用[J].癌症进展,2017,15(8):891-893.
[7] 王庆丽,周庆,瞿元乾. 血清肿瘤标记物CA153、CA125与CEA联合检测在诊断乳腺癌中的临床意义[J].中国地方病防治杂志,2018,33(04):452.
[8] 孙亚楠,毛晓韵,刘晓虹,等. 基底细胞样乳腺癌患者乳腺癌和癌旁正常乳腺组织中MTDH与MMP-9蛋白表达的相关性[J].吉林大学学报(医学版),2016,42(03):530-534. |
|
|
|
2019, Vol. 36 
